ClinicalTrials.gg
TerminatedNCT02379390PRIMCABUpdated Jun 21, 2019Results posted

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

A Phase 2 interventional study of Cabazitaxel XRP6258 and Ezalutamide in Prostate Cancer Metastatic, sponsored by Sanofi. Terminated at 24 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Unsatisfactory patient accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
37th of 46
8 · median 60
Started
2015
with 3 others
Phase 2
28 of 46
5 open now
Registered
21st of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 37th largest by enrollment, is one of 4 that started in 2015, is one of 28 in phase 2, and was the 21st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m\^2) plus prednisone (Arm A) versus either enzalutamide at 160 milligram (mg) once daily or abiraterone acetate at 1000 mg once daily plus prednisone (Arm B) in chemotherapy-naïve participants with metastatic Castration-Resistant Prostate Cancer (mCRPC) who have disease progression while receiving androgen receptor (AR) targeted therapy (abiraterone plus prednisone or enzalutamide) within 12 months of treatment initiation (≤12 months).

Secondary Objective:

  • To compare efficacy for:
  • Prostate-specific antigen (PSA) response rate and Time to PSA progression (TTPP).
  • Progression Free Survival (PFS).
  • Overall Survival (OS).
  • Tumor response rate in participants with measurable disease (RECIST 1.1)
  • Pain response and time to pain progression.
  • Symptomatic skeletal events (SSE) rate and time to occurrence of any SSE.
  • To analyze messenger ribonucleic acids (mRNAs) including androgen-receptor splice variant 7 messenger RNA (AR-V7) as a biomarker in Circulating Tumor Cells (CTCs).
  • To evaluate safety in the 2 treatment arms.
Read the detailed description

The duration of the study per participant was approximately 2 years. Each participant was treated until radiographic disease progression, unacceptable toxicity, or participants refusal of further study treatment, and each participant was followed after completion of study treatment until death, study cutoff date, or withdrawal of participant consent.

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of or cytologically confirmed prostate adenocarcinoma.
  • disease.
  • Progressive disease (PD) while receiving AR targeted therapy with abiraterone acetate or enzalutamide within 12 months of treatment initiation (≤12 months) by at least one of the following:
  • Progression in (RECIST) 1.1.
  • Appearance of 2 or more new bone lesions according to Prostate Cancer Working Group 2 (PCWG2).
  • Rising PSA defined (PCWG2) as at least two consecutive rises in PSA to be documented over a reference value (measure 1) taken at least one week apart.
  • A PSA value of at least 2 nanogram/milliliter (ng/mL) is required at study entry.
  • Effective castration (serum testosterone levels ≤0.5 ng/mL).
  • Prior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Prior chemotherapy for prostate cancer, except estramustine and except /neoadjuvant treatment completed >3 years ago. No further anti-cancer therapy after the previous AR targeted therapy and before inclusion. Prior docetaxel in hormone sensitive setting is allowed if completed >1 year before randomization. Prior immunotherapy is allowed.
  • Less than 28 days elapsed from prior treatment with immunotherapy, radiotherapy, or surgery to the time of randomization.
  • Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute [NCI CTCAE] v4.0) at the time of randomization.
  • (ECOG) performance status >1.
  • History of , uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
  • Prior . Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which treatment has been completed ≥5 years ago and from which the patient has been disease-free for ≥5 years.
  • Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization.
  • Acquired immunodeficiency syndrome (AIDS)-related illnesses or known (HIV) disease requiring antiretroviral treatment.
  • Any severe acute or chronic medical condition including uncontrolled diabetes mellitus, severe renal impairment, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past 6 months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infraction within last 6 months or uncontrolled cardiac arrhythmia), which could impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures.
  • Participants with who do not agree to use accepted and effective method of during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" will be based on the Investigator's judgment.
  • Known allergies, or intolerance to prednisone or of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate 80.
  • Known history of mineralocorticoid excess or deficiency (not applicable to participants who have already been treated with abiraterone acetate in before inclusion).
  • History of seizure, underlying brain injury with loss of consciousness, within the past 12 months, cerebral vascular accident, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold (not applicable to participants who have already been treated with enzalutamide in first line before inclusion).
  • Unable to swallow a whole tablet or capsule.
  • Inadequate organ and bone marrow function as evidenced by:
  • \<10.0 g/dL.
  • \<1.5 x 10\^9/L.
  • count \<100 x 10\^9/L.
  • (AST) and/or Alanine aminotransferase (ALT) >1.5 x (ULN).
  • Total >1.0 x ULN.
  • Potassium \<3.5 mmol/L.
  • Serum albumin \<3.0 g/dL.
  • Class B and C.
  • to the use of treatment.
  • Symptomatic peripheral neuropathy grade ≥2 NCI CTCAE v4.0.
  • Concomitant vaccination with yellow fever vaccine.

The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cabazitaxel

    Participants received Cabazitaxel 25 mg/m\^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.

    Drug: Cabazitaxel XRP6258 · Drug: Prednisone

  • Active comparator
    Abiraterone acetate or Enzalutamide

    Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.

    Drug: Ezalutamide · Drug: Abiraterone acetate · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    rPFS was defined as the time from randomization to the first occurrence of radiological tumor progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or progression of bone lesions using prostate cancer working group 2 (PCWG2) criteria or death due to any cause.

    Time frame: Baseline until tumor progression or bone lesion progression or death due to any cause (maximum duration: 1059 days)

Secondary outcomes

  1. Number of Participants With Prostate Specific Antigen (PSA) Response

    PSA response was defined as decline of serum PSA from baseline by \>= 50 percent (%).

    Time frame: Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)

  2. Progression-free Survival (PFS)

    PFS: time interval between date of randomization to first documentation of tumor progression as per RECIST 1.1.

    Time frame: Baseline upto progression or death due to any cause (maximum duration: 1059 days)

  3. Overall Survival

    Overall Survival was defined as the time interval from the date of randomization to the date of death due to any cause.

    Time frame: Baseline until death or study cut-off date, whichever was earlier (maximum duration: 1059 days)

  4. Time to PSA Progression

    Time to PSA progression was defined as the time interval between the date of randomization and the date of first documented PSA progression as per PCWG2 criteria.

    Time frame: Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)

  5. Number of Participants Achieving Tumor Response

    Tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1.

    Time frame: Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)

  6. Duration of Tumor Response

    Duration of tumor response was defined as the time between the first evaluation at which the tumor response criteria were met and the first documentation of tumor progression.

    Time frame: Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)

  7. Pain Response Using Brief Pain Inventory-Short Form (BPI-SF) for Pain Intensity Score

    Pain response was analyzed using the brief pain inventory-short form (BPI-SF).

    Time frame: Baseline until the end of study (maximum duration: 1059 days)

  8. Time to Pain Progression

    Time to pain progression was defined as the time interval between the date of randomization and the date of the first documented pain progression.

    Time frame: Baseline until disease progression, start of another anticancer therapy or study cut off, whichever came first (maximum duration: 1059 days)

  9. Percentage of Participants With Symptomatic Skeletal Event (SSE)

    SSE was the occurrence of a new symptomatic pathological fracture, or the use of external beam radiation to relieve bone pain, or the occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention.

    Time frame: Baseline until the end of study (maximum duration: 1059 days)

  10. Time to Occurrence of Any Symptomatic Skeletal Events (SSE)

    Time to SSE was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SSE, whichever is earlier.

    Time frame: Baseline up to occurrence of the first event defining a SSE (maximum duration: 1059 days)

07

Results

Posted Jun 21, 2019

Participant flow

Study conducted at 6 active centers in United States and Canada. A total of 8 participants were enrolled between 17 June 2015 to 13 Mar 2016. Total 15 participants were screened, out of which 7 were screen failures and 8 were randomized and treated in the study. Study was terminated early due to very low recruitment rate in both countries involved.

Participant flow — Overall Study
MilestoneCabazitaxelAbiraterone Acetate or Enzalutamide
Started44
Completed22
Not completed22
Withdrew: Adverse event11
Withdrew: Investigator's decision10
Withdrew: Study termination01

Outcome measures

PrimaryRadiographic Progression-Free Survival (rPFS)

rPFS was defined as the time from randomization to the first occurrence of radiological tumor progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or progression of bone lesions using prostate cancer working group 2 (PCWG2) criteria or death due to any cause.

Time frame:
Baseline until tumor progression or bone lesion progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Prostate Specific Antigen (PSA) Response

PSA response was defined as decline of serum PSA from baseline by \>= 50 percent (%).

Time frame:
Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS)

PFS: time interval between date of randomization to first documentation of tumor progression as per RECIST 1.1.

Time frame:
Baseline upto progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall Survival was defined as the time interval from the date of randomization to the date of death due to any cause.

Time frame:
Baseline until death or study cut-off date, whichever was earlier (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryTime to PSA Progression

Time to PSA progression was defined as the time interval between the date of randomization and the date of first documented PSA progression as per PCWG2 criteria.

Time frame:
Baseline up to PSA progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryNumber of Participants Achieving Tumor Response

Tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1.

Time frame:
Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryDuration of Tumor Response

Duration of tumor response was defined as the time between the first evaluation at which the tumor response criteria were met and the first documentation of tumor progression.

Time frame:
Baseline up to disease progression or death due to any cause (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryPain Response Using Brief Pain Inventory-Short Form (BPI-SF) for Pain Intensity Score

Pain response was analyzed using the brief pain inventory-short form (BPI-SF).

Time frame:
Baseline until the end of study (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryTime to Pain Progression

Time to pain progression was defined as the time interval between the date of randomization and the date of the first documented pain progression.

Time frame:
Baseline until disease progression, start of another anticancer therapy or study cut off, whichever came first (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Symptomatic Skeletal Event (SSE)

SSE was the occurrence of a new symptomatic pathological fracture, or the use of external beam radiation to relieve bone pain, or the occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention.

Time frame:
Baseline until the end of study (maximum duration: 1059 days)

No measurements were reported for this outcome.

SecondaryTime to Occurrence of Any Symptomatic Skeletal Events (SSE)

Time to SSE was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SSE, whichever is earlier.

Time frame:
Baseline up to occurrence of the first event defining a SSE (maximum duration: 1059 days)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline until the end of study (maximum duration: 1059 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabazitaxel0/4 (0%)1/4 (25%)3/4 (75%)
Enzalutamide or Abiraterone0/4 (0%)2/4 (50%)2/4 (50%)
Abiraterone0/1 (0%)0/1 (0%)1/1 (100%)
Enzalutamide0/3 (0%)2/3 (66.7%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventCabazitaxelEnzalutamide or AbirateroneAbirateroneEnzalutamide
SeizureNervous system disorders0/41/40/11/3
HaematuriaRenal and urinary disorders0/41/40/11/3
PancytopeniaBlood and lymphatic system disorders1/40/40/10/3
FallInjury, poisoning and procedural complications0/41/40/10/3
Humerus FractureInjury, poisoning and procedural complications0/41/40/10/3
Most frequent other events
Showing 10 of 31
Most frequent other events
EventCabazitaxelEnzalutamide or AbirateroneAbirateroneEnzalutamide
HypophosphataemiaMetabolism and nutrition disorders0/41/41/10/3
Hot FlushVascular disorders0/41/41/10/3
DiarrhoeaGastrointestinal disorders2/40/40/10/3
Oedema PeripheralGeneral disorders2/40/40/10/3
Muscular WeaknessMusculoskeletal and connective tissue disorders2/40/40/10/3
Neuropathy PeripheralNervous system disorders2/40/40/10/3
NauseaGastrointestinal disorders1/41/40/11/3
VomitingGastrointestinal disorders1/41/40/11/3
InfluenzaInfections and infestations0/41/40/11/3
FallInjury, poisoning and procedural complications0/41/40/11/3

Baseline characteristics

All randomized participants who were exposed to at least one dose of study treatment.

Age, Categorical
Age, Categorical(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
<=18 years000
Between 18 and 65 years101
>=65 years347
Sex: Female, Male
Sex: Female, Male(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
Female000
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
Hispanic or Latino000
Not Hispanic or Latino448
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CabazitaxelAbiraterone Acetate or EnzalutamideTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White347
More than one race000
Unknown or Not Reported000
08

Study locations

24 sites
  • Investigational Site Number 840030
    Muscle Shoals, Alabama 35661, United States
  • Investigational Site Number 840024
    Anchorage, Alaska 99508, United States
  • Investigational Site Number 840028
    Anaheim, California 92801, United States
  • Investigational Site Number 840004
    Sacramento, California 95817, United States
  • Investigational Site Number 840002
    Boca Raton, Florida 33486, United States
  • Investigational Site Number 840027
    Lakeland, Florida 33805, United States
  • Investigational Site Number 840006
    Port Saint Lucie, Florida 34952, United States
  • Investigational Site Number 840015
    Ottawa, Illinois 61350, United States
  • Investigational Site Number 840001
    Covington, Louisiana 70433, United States
  • Investigational Site Number 840017
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840012
    Rockville, Maryland 20850, United States
  • Investigational Site Number 840026
    Omaha, Nebraska 68198, United States
  • Investigational Site Number 840022
    Canton, Ohio 44718, United States
  • Investigational Site Number 840016
    Myrtle Beach, South Carolina 29572, United States
  • Investigational Site Number 124003
    Edmonton, T6G 1Z2, Canada
  • Investigational Site Number 124010
    Greenfield Park, J4V2H1, Canada
  • Investigational Site Number 124005
    Hamilton, L8V 5C2, Canada
  • Investigational Site Number 124004
    London, N6A 4L6, Canada
  • Investigational Site Number 124002
    Montreal, H2L 4M1, Canada
  • Investigational Site Number 124006
    Montreal, H2W1S6, Canada
  • Investigational Site Number 124007
    Ottawa, K1H8L6, Canada
  • Investigational Site Number 124009
    Quebec, G1R 2J6, Canada
  • Investigational Site Number 124008
    Saskatoon, S7N4H4, Canada
  • Investigational Site Number 124001
    Vancouver, N5Z4E6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in May 2018, 34 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2015
First posted
Mar 4, 2015
StartActual
Jun 17, 2015
Primary completionActual
May 10, 2018
CompletionActual
May 10, 2018
Results first posted
Jun 21, 2019
Last update
Jun 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02379390
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2015
Start date
Jun 17, 2015
Primary completion
May 10, 2018
Completion
May 10, 2018
Results posted
Jun 21, 2019
Last update
Jun 21, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion